Because so many things can cause abnormalliverfunction, it may be necessary to start and stop a cholesterol-lowering drug several times while conducting the tests to see whether it is the cause of the problem.
The most common adverse reactions in patients treated with KYNAMRO that led to treatment discontinuation and occurred at a rate greater than placebo were: injection site reactions (5.0%), alanine aminotransferase (ALT) increased (3.4%), flu-like symptoms (2.7%), aspartate aminotransferase (AST) increased (2.3%), and liverfunction test abnormal (1.5%).